These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3161669)

  • 1. The effect of ipratropium bromide (Atrovent) on the air conditioning capacity of the nose.
    Kumlien J; Drettner B
    Clin Otolaryngol Allied Sci; 1985 Jun; 10(3):165-8. PubMed ID: 3161669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipratropium bromide increases the ability of the nose to warm and humidify air.
    Assanasen P; Baroody FM; Rouadi P; Naureckas E; Solway J; Naclerio RM
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):1031-7. PubMed ID: 10988126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal ipratropium: inhibition of methacholine induced hypersecretion.
    Borum P
    Rhinology; 1978 Dec; 16(4):225-33. PubMed ID: 154164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ipratropium bromide on nasal mucociliary transport.
    Ohi M; Sakakura Y; Murai S; Miyoshi Y
    Rhinology; 1984 Dec; 22(4):241-6. PubMed ID: 6240764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal ipratropium in the treatment of vasomotor rhinitis.
    Jokinen K; Sipilä P
    Rhinology; 1983 Dec; 21(4):341-5. PubMed ID: 6229864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients.
    Malmberg H; Grahne B; Holopainen E; Binder E
    Clin Otolaryngol Allied Sci; 1983 Aug; 8(4):273-6. PubMed ID: 6228347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasomotor rhinitis and the systemic absorption of ipratropium bromide.
    Kaila T; Suonpää J; Grénman R; Iisalo E
    Rhinology; 1990 Jun; 28(2):83-9. PubMed ID: 2143593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ipratropium bromide on nasal hypersecretion induced by methacholine in patients with vasomotor rhinitis. A double-blind, cross-over, placebo-controlled and randomized dose-response study.
    Sjögren I; Jonsson L; Köling A; Jansson C; Osterman K; Håkansson B
    Acta Otolaryngol; 1988; 106(5-6):453-9. PubMed ID: 2974675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution.
    Rafferty P; Beasley R; Holgate ST
    Thorax; 1988 Jun; 43(6):446-50. PubMed ID: 2971274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipratropium bromide (Atrovent nasal spray) reduces the nasal response to methacholine.
    Baroody FM; Majchel AM; Roecker MM; Roszko PJ; Zegarelli EC; Wood CC; Naclerio RM
    J Allergy Clin Immunol; 1992 Jun; 89(6):1065-75. PubMed ID: 1535082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ipratropium bromide (atrovent) inhalation in chronic bronchitis.
    Kashyap S; Jindal SK; Malik SK
    Indian J Chest Dis Allied Sci; 1985; 27(3):137-40. PubMed ID: 2943673
    [No Abstract]   [Full Text] [Related]  

  • 12. Control of the hypersecretion of vasomotor rhinitis by topical ipratropium bromide.
    Dolovich J; Kennedy L; Vickerson F; Kazim F
    J Allergy Clin Immunol; 1987 Sep; 80(3 Pt 1):274-8. PubMed ID: 2957416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis.
    Knight A; Kazim F; Salvatori VA
    Ann Allergy; 1986 Nov; 57(5):348-54. PubMed ID: 2946252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life.
    Georgitis JW; Banov C; Boggs PB; Dockhorn R; Grossman J; Tinkelman D; Roszko P; Wood C
    Clin Exp Allergy; 1994 Nov; 24(11):1049-55. PubMed ID: 7874603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions.
    Wagenmann M; Baroody FM; Jankowski R; Nadal JC; Roecker-Cooper M; Wood CC; Naclerio RM
    Clin Exp Allergy; 1994 Mar; 24(3):288-90. PubMed ID: 8012861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of nasal mucosa to histamine or methacholine challenge: use of a quantitative method to examine the modulatory effects of atropine and ipratropium bromide.
    Naclerio RM; Baroody FM
    J Allergy Clin Immunol; 1992 Dec; 90(6 Pt 2):1051-4. PubMed ID: 1460207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nasal hypersecretion treated with ipratropium].
    Borum P
    Lakartidningen; 1980 May; 77(21):2038-9. PubMed ID: 6447235
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of intranasal Atrovent in the treatment of vasomotor rhinitis.
    Hosen H
    Ann Allergy; 1987 Nov; 59(5):384. PubMed ID: 2961291
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of Atrovent (ipratropium bromide) on the mechanics of respiration in patients with chronic obstructive pulmonary disease].
    Malinowski R; Frank-Piskorska A; Wasek Z; Koczorowski T
    Pneumonol Pol; 1986 Mar; 54(3):91-5. PubMed ID: 2942842
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term safety and efficacy study of intranasal ipratropium bromide.
    Milford CA; Mugliston TA; Lund VJ; Mackay IS
    J Laryngol Otol; 1990 Feb; 104(2):123-5. PubMed ID: 2139094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.